electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO). The two patents were issued on December 26, 2023, and relate to electroCore's non-invasive vagus nerve stimulation (nVNS) technology:
- US Patent No. 11,850,056 entitled "Devices and Methods for Remote Therapy and Patient Monitoring" generally relates to systems and methods for treating medical conditions that include delivering an nVNS therapy regimen, detecting a heart rate variability (HRV) of the patient, and comparing the HRV with data related to parameters of the therapy regimen.
- US Patent No. 11,854,695 entitled "Medical Devices for Treating Medical Conditions" generally relates to a medical device that includes a signal generator for applying electrical impulses to the patient for a period of time (i.e., a single dose), wherein the device is configured to deactivate upon a first occurrence of a specific number of single doses being applied to the patient or a specific time elapsing after the first dose is applied.